275 related articles for article (PubMed ID: 20569725)
1. A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm.
Stiell IG; Roos JS; Kavanagh KM; Dickinson G
Am Heart J; 2010 Jun; 159(6):1095-101. PubMed ID: 20569725
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation.
Pratt CM; Roy D; Torp-Pedersen C; Wyse DG; Toft E; Juul-Moller S; Retyk E; Drenning DH;
Am J Cardiol; 2010 Nov; 106(9):1277-83. PubMed ID: 21029824
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of vernakalant for the conversion of atrial fibrillation to sinus rhythm; a phase 3b randomized controlled trial.
Beatch GN; Mangal B
BMC Cardiovasc Disord; 2016 May; 16():113. PubMed ID: 27233239
[TBL] [Abstract][Full Text] [Related]
4. Vernakalant in the management of atrial fibrillation.
Cheng JW
Ann Pharmacother; 2008 Apr; 42(4):533-42. PubMed ID: 18334607
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of novel atrial-selective antiarrhythmic agent vernakalant hydrochloride injection (RSD1235): influence of CYP2D6 expression and other factors.
Mao ZL; Wheeler JJ; Clohs L; Beatch GN; Keirns J
J Clin Pharmacol; 2009 Jan; 49(1):17-29. PubMed ID: 18927241
[TBL] [Abstract][Full Text] [Related]
6. Vernakalant: conversion of atrial fibrillation in patients with ischemic heart disease.
Torp-Pedersen C; Camm AJ; Butterfield NN; Dickinson G; Beatch GN
Int J Cardiol; 2013 Jun; 166(1):147-51. PubMed ID: 22108512
[TBL] [Abstract][Full Text] [Related]
7. A randomized, placebo-controlled study of vernakalant (oral) for the prevention of atrial fibrillation recurrence after cardioversion.
Torp-Pedersen C; Raev DH; Dickinson G; Butterfield NN; Mangal B; Beatch GN
Circ Arrhythm Electrophysiol; 2011 Oct; 4(5):637-43. PubMed ID: 21841207
[TBL] [Abstract][Full Text] [Related]
8. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial.
Kowey PR; Dorian P; Mitchell LB; Pratt CM; Roy D; Schwartz PJ; Sadowski J; Sobczyk D; Bochenek A; Toft E;
Circ Arrhythm Electrophysiol; 2009 Dec; 2(6):652-9. PubMed ID: 19948506
[TBL] [Abstract][Full Text] [Related]
9. Vernakalant hydrochloride: A novel atrial-selective agent for the cardioversion of recent-onset atrial fibrillation in the emergency department.
Stiell IG; Dickinson G; Butterfield NN; Clement CM; Perry JJ; Vaillancourt C; Calder LA
Acad Emerg Med; 2010 Nov; 17(11):1175-82. PubMed ID: 21175515
[TBL] [Abstract][Full Text] [Related]
10. A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation.
Roy D; Rowe BH; Stiell IG; Coutu B; Ip JH; Phaneuf D; Lee J; Vidaillet H; Dickinson G; Grant S; Ezrin AM; Beatch GN;
J Am Coll Cardiol; 2004 Dec; 44(12):2355-61. PubMed ID: 15607398
[TBL] [Abstract][Full Text] [Related]
11. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation.
Camm AJ; Capucci A; Hohnloser SH; Torp-Pedersen C; Van Gelder IC; Mangal B; Beatch G;
J Am Coll Cardiol; 2011 Jan; 57(3):313-21. PubMed ID: 21232669
[TBL] [Abstract][Full Text] [Related]
12. Vernakalant, a mixed sodium and potassium ion channel antagonist that blocks K(v)1.5 channels, for the potential treatment of atrial fibrillation.
Billman GE
Curr Opin Investig Drugs; 2010 Sep; 11(9):1048-58. PubMed ID: 20730700
[TBL] [Abstract][Full Text] [Related]
13. Vernakalant hydrochloride for the treatment of atrial fibrillation.
Kozlowski D; Budrejko S; Lip GY; Mikhailidis DP; Rysz J; Raczak G; Banach M
Expert Opin Investig Drugs; 2009 Dec; 18(12):1929-37. PubMed ID: 19938903
[TBL] [Abstract][Full Text] [Related]
14. Conversion efficacy of intravenous ibutilide compared with intravenous amiodarone in patients with recent-onset atrial fibrillation and atrial flutter.
Kafkas NV; Patsilinakos SP; Mertzanos GA; Papageorgiou KI; Chaveles JI; Dagadaki OK; Kelesidis KM
Int J Cardiol; 2007 Jun; 118(3):321-5. PubMed ID: 17049640
[TBL] [Abstract][Full Text] [Related]
15. Intravenous vernakalant: a review of its use in the management of recent-onset atrial fibrillation.
Duggan ST; Scott LJ
Drugs; 2011 Jan; 71(2):237-52. PubMed ID: 21275448
[TBL] [Abstract][Full Text] [Related]
16. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial.
Roy D; Pratt CM; Torp-Pedersen C; Wyse DG; Toft E; Juul-Moller S; Nielsen T; Rasmussen SL; Stiell IG; Coutu B; Ip JH; Pritchett EL; Camm AJ;
Circulation; 2008 Mar; 117(12):1518-25. PubMed ID: 18332267
[TBL] [Abstract][Full Text] [Related]
17. Spotlight on intravenous vernakalant in recent-onset atrial fibrillation.
Duggan ST; Scott LJ
Drugs Aging; 2011 Jun; 28(6):501-4. PubMed ID: 21639409
[TBL] [Abstract][Full Text] [Related]
18. Conversion of Atrial Fibrillation after Cardiosurgical Procedures by Vernakalant® as an Atrial Repolarization Delaying Agent (ARDA).
Dalyanoglu H; Mehdiani A; Minol JP; Sipahi NF; Aubin H; Boeken U; Müller A; Makimoto H; Lichtenberg A; Korbmacher B
Heart Surg Forum; 2018 May; 21(3):E201-E208. PubMed ID: 29893681
[TBL] [Abstract][Full Text] [Related]
19. Predictors of successful cardioversion with vernakalant in patients with recent-onset atrial fibrillation.
Mochalina N; Juhlin T; Öhlin B; Carlson J; Holmqvist F; Platonov PG
Ann Noninvasive Electrocardiol; 2015 Mar; 20(2):140-7. PubMed ID: 25040826
[TBL] [Abstract][Full Text] [Related]
20. [Vernakalant: a novel antiarrhythmic drug for the rapid conversion of atrial fibrillation to sinus rhythm].
Hirt MN; Eschenhagen T
Dtsch Med Wochenschr; 2010 May; 135(19):971-6. PubMed ID: 20446233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]